U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO11.ClH
Molecular Weight 579.9812
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXORUBICIN HYDROCHLORIDE

SMILES

C[C@@]1([H])[C@]([H])([C@]([H])(C[C@@]([H])(O1)O[C@@]2([H])C[C@@](Cc3c2c(c4c(C(=O)c5cccc(c5C4=O)OC)c3O)O)(C(=O)CO)O)N)O.Cl

InChI

InChIKey=MWWSFMDVAYGXBV-RUELKSSGSA-N
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H29NO11
Molecular Weight 543.5203
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.drugs.com/dosage/doxorubicin.html

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

CNS Activity

Curator's Comment:: Doxorubicin did not have access to areas of the brain within the blood-brain barrier, passed from the blood into the nervous parenchyma in those areas of the brain located outside the blood-brain barrier in mice

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

816480000000
Primary
DOXIL

Approved Use

Indicated for: Ovarian cancer After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma

Launch Date

816480000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 μM
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.4 μM × h
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
34.8 h
60 mg/m² 1 times / day steady-state, intravenous
dose: 60 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DOXORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
25%
DOXORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Other AEs: Mucositis, Chills...
Other AEs:
Mucositis (severe, 1 patient)
Chills (1 patient)
Pyrexia (1 patient)
Sources:
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M
Sources:
Other AEs: Sinus tachycardia, Neutropenia...
Other AEs:
Sinus tachycardia (1 patient)
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (1 patient)
Mucositis (severe, 1 patient)
Sepsis (severe, 1 patient)
Sources:
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Disc. AE: Tissue injury...
Other AEs: Acute myeloid leukaemia, Myelodysplastic syndrome...
AEs leading to
discontinuation/dose reduction:
Tissue injury (severe)
Other AEs:
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelosuppression (severe)
Sources:
300 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 300 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Other AEs: Cardiomyopathy...
AEs

AEs

AESignificanceDosePopulation
Chills 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Pyrexia 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Mucositis severe, 1 patient
150 mg/m2 1 times / day multiple, intravenous
Overdose
Dose: 150 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Sinus tachycardia 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M
Sources:
Thrombocytopenia 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M
Sources:
Neutropenia grade 4, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M
Sources:
Mucositis severe, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M
Sources:
Sepsis severe, 1 patient
300 mg/m2 single, intravenous
Overdose
Dose: 300 mg/m2
Route: intravenous
Route: single
Dose: 300 mg/m2
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M
Sources:
Acute myeloid leukaemia
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Myelodysplastic syndrome
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Myelosuppression severe
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Tissue injury severe
Disc. AE
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Cardiomyopathy
300 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 300 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 1 times / 3 weeks
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes [Km 5.2 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Myocardial injury induced by a single dose of adriamycin: an electron microscopic study.
1976 Sep-Oct
Experimental animal models of adriamycin cardiotoxicity.
1979 May
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
1999
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
1999
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
1999 Apr
Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
1999 Apr 29
Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
1999 Aug
Sodium bicarbonate treatment reduces renal injury, renal production of transforming growth factor-beta, and urinary transforming growth factor-beta excretion in rats with doxorubicin-induced nephropathy.
1999 Aug
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
1999 Dec
Doxorubicin-induced cardiomyopathy.
1999 Feb 25
[Changes in left ventricular function during chemotherapy with doxorubicin].
1999 Jul
Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma.
1999 Jul
Effect of allopurinol in the course of adriamycin induced nephropathy.
1999 Mar
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
1999 May
Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
1999 May
Primary desmoplastic small cell tumor of soft tissues and bone of the hand.
1999 Nov
Low-dose vincristine-associated bilateral vocal cord paralysis.
1999 Oct
A canine model of heart failure by intracoronary adriamycin injection: hemodynamic and energetic results.
1999 Sep
Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin.
1999 Sep
Glomerular basement membrane anionic sites in adriamycin nephropathy: effect of saline loading and nitric oxide modulation.
2000 Apr
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
2000 Aug
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.
2000 Aug
Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells.
2000 Aug 15
High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
2000 Dec
Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription.
2000 Dec
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
2000 Dec 1
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
2000 Dec 15
Neural crest-derived defects in experimental esophageal atresia.
2000 Feb
Curcumin prevents adriamycin nephrotoxicity in rats.
2000 Jan
Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription.
2000 Jan 7-21
Doxorubicin-induced cardiomyopathy.
2000 Jul
Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice.
2000 Jul
Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats.
2000 Jun
Beta-blockade in adriamycin-induced cardiomyopathy.
2000 Jun
Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells.
2000 Mar 6
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
2000 May
Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
2000 May
Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
2000 Nov
Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method.
2000 Nov-Dec
Renal antioxidant enzymes and fibrosis-related markers in the rat adriamycin model.
2000 Oct
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
2000 Sep 15
ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy.
2001
Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
2001 Jan
Low-grade ovarian cancer in an adolescent patient.
2001 Jan
Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
2001 Jan 1
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
2001 Jan 1
Characterization of adriamycin-induced G2 arrest and its abrogation by caffeine in FL-amnion cells with or without p53.
2001 Jan 1
Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells.
2001 Jan 26
Human mismatch repair and G*T mismatch binding by hMutSalpha in vitro is inhibited by adriamycin, actinomycin D, and nogalamycin.
2001 Mar 30
Patents

Sample Use Guides

When used in combination with other chemotherapy drugs, the most commonly used dosage of doxorubicin is 40 to 60 mg/m2 IV every 21 to 28 days. Alternatively, 60 to 75 mg/m2 IV once every 21 days.
Route of Administration: Intravenous
Alkalinization of extracellular pH by urease (2 U/ml) and urea (> or = 2 mM) was found to enhance the antitumor efficacy of doxorubicin (50 uM)
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:17:43 UTC 2021
Edited
by admin
on Fri Jun 25 21:17:43 UTC 2021
Record UNII
82F2G7BL4E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXORUBICIN HYDROCHLORIDE
EMA EPAR   EP   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
IMX-110 COMPONENT DOXORUBICIN HYDROCHLORIDE
Common Name English
(8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE HYDROCHLORIDE
Common Name English
ADRIAMYCIN, HYDROCHLORIDE
Common Name English
DOXORUBICIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP-RS]
Common Name English
DOXORUBICIN HYDROCHLORIDE [EMA EPAR]
Common Name English
CAELYX
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME [VANDF]
Common Name English
DOXORUBICINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
DOXORUBICIN HYDROCHLORIDE [MART.]
Common Name English
DOXIL
Brand Name English
DOXORUBICIN HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP]
Common Name English
HYDROXYDAUNOMYCIN HYDROCHLORIDE
Common Name English
DOXORUBICIN HCL
Common Name English
DOXORUBICIN HYDROCHLORIDE [VANDF]
Common Name English
DOXORUBICIN HYDROCHLORIDE [WHO-IP]
Common Name English
ADRIAMYCIN
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME
VANDF  
Common Name English
ADRIABLASTINA CS
Common Name English
ADRIAMYCIN [IARC]
Common Name English
RUBEX
Brand Name English
LIPOSOMAL DOXORUBICIN HYDROCHLORIDE [WHO-DD]
Common Name English
5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYLACETYL)-1-METHOXY-, HYDROCHLORIDE (8S-CIS)-
Common Name English
DOXORUBICIN LIPOSOMAL COMPLEX OF THE HYDROCHLORIDE [MI]
Common Name English
DOXORUBICIN HYDROCHLORIDE [JAN]
Common Name English
DOXORUBICIN HYDROCHLORIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/833
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
NCI_THESAURUS C67502
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
EMA ASSESSMENT REPORTS MYOCET (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 229006
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 191704
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 210705
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 628318
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
FDA ORPHAN DRUG 311910
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
246-818-3
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
FDA UNII
82F2G7BL4E
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
MERCK INDEX
M4757
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY Merck Index
RXCUI
142433
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DOXORUBICIN HYDROCHLORIDE
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY Description: A red-orange, crystalline powder. Solubility: Soluble in water and methanol R; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Doxorubicin hydrochloride should be kept in a tightly closed container. Additional information: Doxorubicin hydrochloride is hygroscopic; it is poisonous: CAUTION: Doxorubicin hydrochloride must behandled with care, avoiding contact with the skin and inhalation of airborne particles. Definition. Doxorubicin hydrochloride contains not less than 97.0% and not more than 102.0% of C27H29NO11,HCl, calculatedwith reference to the anhydrous substance.
EVMPD
SUB06391MIG
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
CAS
25316-40-9
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
PUBCHEM
443939
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
ChEMBL
CHEMBL53463
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
NCI_THESAURUS
C1326
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
RXCUI
466523
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
ALTERNATIVE
EVMPD
SUB01827MIG
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
EVMPD
SUB126795
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
ALTERNATIVE
DRUG BANK
DBSALT000060
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
USP_CATALOG
1225703
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY USP-RS
EPA CompTox
25316-40-9
Created by admin on Fri Jun 25 21:17:43 UTC 2021 , Edited by admin on Fri Jun 25 21:17:43 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY